<DOC>
	<DOCNO>NCT01953328</DOCNO>
	<brief_summary>The primary objective study evaluate effect 12 week subcutaneous evolocumab administer every 2 week month , compare placebo , percent change baseline LDL-C use combination statin therapy adult high cardiovascular risk hyperlipidemia mixed dyslipidemia .</brief_summary>
	<brief_title>Study Low-Density Lipoprotein Cholesterol ( LDL-C ) Reduction Using Evolocumab ( AMG 145 ) Japanese Patients With Advanced Cardiovascular Risk</brief_title>
	<detailed_description>After screen placebo run-in period , eligible patient randomize 1:1 ratio 1 2 open-label background statin treatment ( atorvastatin 5 mg 20 mg daily [ QD ] ) enter 4-week lipid stabilization period . After lipid stabilization period , eligible patient randomize 1:1:1:1 ratio investigational product ( evolocumab placebo ) 12-week treatment period . Both randomization stratify subject diagnosis lipid-lowering therapy follow : - current prior diagnosis heterozygous familial hypercholesterolemia ( HeFH ) - diagnosis HeFH receive intensive lipid-lowering therapy - diagnosis HeFH receive non-intensive lipid-lowering therapy . A participant consider randomize study successfully complete screen period , meet inclusion/exclusion criterion include meet final laboratory safety criterion , undergo randomization procedure .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female , Japanese adult , 2085 year age ; Subjects stable dose statin great equal 4 week ; Fasting LDLC great equal 100 mg/dL ; Fasting triglycerides less equal 400 mg/dL ; Subject high risk cardiovascular event . New York heart Association ( NYHA ) III IV heart failure ; Uncontrolled cardiac arrhythmia ; Uncontrolled hypertension ; Type 1 diabetes , poorly control type 2 diabetes ; Uncontrolled hypothyroidism hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Japanese , high cholesterol , LDL-C , High Cardiovascular Risk</keyword>
</DOC>